Comparative Pharmacology
Head-to-head clinical analysis: CYCRIN versus NORETHINDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCRIN versus NORETHINDRONE.
CYCRIN vs NORETHINDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
None Documented
None Documented
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Category C
Category D/X
Progestin
Progestin